Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohortNan Wu, Lai Wei, Huiying Rao et al.|Chinese Medical Journal|2020Cited by 33
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trialYanhang Gao, Jian-Mei Lin, Xiaofeng Wen et al.|Liver International|2020Cited by 22
The prevalence and risk factors of metabolic syndrome among hepatitis C patients in Chinese Han populationYinghui Gao, Lai Wei, Huiying Rao et al.|Zhonghua chuanranbing zazhi|2018Cited by 0